Washington Post: Trump politicizes promising coronavirus antibody treatments, erroneously calling them a ‘cure’

Washington Post: Trump politicizes promising coronavirus antibody treatments, erroneously calling them a ‘cure’. “Trump claimed on videos posted on Twitter Wednesday and Thursday that the drug he received, a cocktail of laboratory-made antibodies from Regeneron Pharmaceuticals, is a “cure” that would soon be broadly available — even as the company disclosed that in the next few months, it would have enough supply to treat only the number of Americans sickened in the last week, or about 300,000 doses. A similar antibody drug, made by Eli Lilly & Co., shows similar promise but will also be in short supply, with about 1 million doses by year’s end.”

MIT Technology Review: Trump’s antibody treatment was tested using cells originally derived from an abortion

MIT Technology Review: Trump’s antibody treatment was tested using cells originally derived from an abortion. “The emergency antibody that Trump received last week was developed with the use of a cell line originally derived from abortion tissue, according to Regeneron Pharmaceuticals, the company that developed the experimental drug. The Trump administration has taken an increasingly firm line against medical research using fetal tissue from abortions.”

CNBC: Eli Lilly reports a reduced rate of hospitalization for coronavirus patients using its antibody treatment

CNBC: Eli Lilly reports a reduced rate of hospitalization for coronavirus patients using its antibody treatment. “Eli Lilly said Wednesday its antibody-based drug appears to have reduced the rate of hospitalization for coronavirus patients recently diagnosed with mild-to-moderate symptoms. The U.S. drugmaker said it tested three different doses of LY-CoV555 against a placebo in a trial enrolling roughly 450 patients. The middle dose of 2,800 mg met the trial’s target of significantly reducing the presence of SARS-CoV-2 after 11 days.”

MIT Technology Review: The race to find a covid-19 drug in the blood of survivors

MIT Technology Review: The race to find a covid-19 drug in the blood of survivors. “In the US, a slow and confused rollout of coronavirus testing helped the new virus get a foothold and cause what is now a raging outbreak. But drug and biotech companies have been searching for a cure since January, when the severity of the epidemic in China became evident. Among the most promising candidates are antibody drugs, a type that already accounts for most of the top-selling medicines in the US.”